Instil Bio, Inc. (TIL) Stock Price & Analysis
Instil Bio, Inc. (TIL) fell 0.74% to USD 8.02 as of June 10, 2026 at 00:48 UTC, according to Nexqual real-time market data.
TIL last closed at USD 8.08; the session ranged USD 7.96–8.15 on volume of 16,123 shares. Market capitalization is $54.39M, with a 52-week range of USD 5.67–42.79 (NCM). Source: Nexqual, June 10, 2026 at 00:48 UTC.
Key Statistics (as of June 10, 2026 at 00:48 UTC)
| Price | USD 8.02 |
|---|---|
| Change | ▼ 0.74% (down) |
| Previous Close | USD 8.08 |
| Open | USD 8.15 |
| Day Range | USD 7.96 – 8.15 |
| 52-Week Range | USD 5.67 – 42.79 |
| Volume | 16,123 shares |
| Market Cap | $54.39M |
| Exchange | NCM |
Technical Analysis (TIL)
Nexqual's technical model rates TIL "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:48 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.04 (neutral) |
| vs SMA50 | Below (USD 8.18) |
| MACD | -0.02 (negative) |
Analyst Ratings (TIL)
Wall Street analysts rate TIL "None" based on 1 analysts, with a mean price target of USD 7 (range USD 7–7), per Nexqual as of June 10, 2026 at 00:48 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 7 |
| High Target | USD 7 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 0 / 2 / 0 |
Earnings (TIL)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.62 vs est -0.59 ▼ miss |
| 2025-12-31 | USD -0.97 vs est -3.78 ▲ beat |
| 2025-09-30 | USD -1.75 vs est -3.04 ▲ beat |
| 2025-06-30 | USD -2.88 vs est -2.44 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:48 UTC.
Financials & Fundamentals (TIL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -37.07% |
| Debt / Equity | 76.95 |
| Current Ratio | 39.87 |
| Total Cash | $74.57M |
| Total Debt | $85.19M |
| Free Cash Flow | $-23.89M |
Source: Nexqual, June 10, 2026 at 00:48 UTC.
Financial Health Score (TIL)
Nexqual rates Instil Bio, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:48 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $75M cash vs $85M debt |
| Cash Flow | Weak — Operating cash flow -$34M |
| Efficiency | Critical — ROE -37%, ROA -12.7% |
Ownership (TIL)
| Insider Ownership | +6.29% |
|---|---|
| Institutional Ownership | +62.20% |
| Shares Outstanding | 6.78M |
| Float | 3.62M |
| Short % of Float | +5.78% |
Source: Nexqual, June 10, 2026 at 00:48 UTC.
Leadership (TIL)
Instil Bio, Inc. is led by Bronson Crouch (age 52), Chairman & CEO, per Nexqual as of June 10, 2026 at 00:48 UTC.
| Chairman & CEO | Bronson Crouch (age 52) |
|---|---|
| CFO & Chief Business Officer | Sandeep Laumas (age 56) |
Major Backers & Investors (TIL)
Notable institutional backers of Instil Bio, Inc. include Curative Ventures V LLC, BML Capital Management, LLC, CPMG INC, according to Nexqual as of June 10, 2026 at 00:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Curative Ventures V LLC | 28% |
| BML Capital Management, LLC | 9.52% |
| CPMG INC | 6.06% |
| Vivo Capital, LLC | 4.32% |
| Kalehua Capital Management LLC | 2.7% |
| Millennium Management | 1.96% |
| Renaissance Technologies | 0.87% |
| Nomura Asset Management International Inc | 0.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.14% |
| BlackRock | 0.91% |
Source: Nexqual, June 10, 2026 at 00:48 UTC.
From Instil Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Any marketing application for a drug or biologic submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.
- Prior to developing AXN-2510, our development efforts were focused on pursuing the development of cell therapies, including our proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for the treatment of cancer.
- We believe that our approach, strategy and experience provide us with certain competitive advantages.
Partnerships
- The license and collaboration agreement with ImmuneOnco was terminated in January 2026.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| SNSE | Sensei Biotherapeutics, Inc. | USD 12.63 | ▼ 13.79% |
| LYEL | Lyell Immunopharma, Inc. | USD 12.7 | ▲ 6.1% |
| ANNX | Annexon, Inc. | USD 5.2 | ▼ 1.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:48 UTC. This page is informational and not investment advice.